Platelet hyperaggregability to platelet activating factor (PAF) in non-ST elevation acute coronary syndromes

Current Medical Research and Opinion

Volumn 18, Issue 2, 2002, Pages 108-112

  Michalis, L K ^a   Tambaki, A P ^a   Katsouras, C S ^a   Goudevenos, J A ^a   Kolettis, T ^a   Adamides, K ^a   Tselepis, A D ^a   Sideris, Dimitris A ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Non ST elevation acute coronary syndromes; PAF; Platelets

Indexed keywords

THROMBOCYTE ACTIVATING FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NORMAL VALUE; PATHOPHYSIOLOGY; PATIENT CODING; PLASMA; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CORONARY DISEASE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION; SENSITIVITY AND SPECIFICITY; SYNDROME;

EID: 0036244672     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125000381     Document Type: Article

References (25)

1. Platelet activation in unstable coronary artery disease
2. Acute myocardial ischaemia: Role of atherosclerosis, thrombosis, platelet activation, coronary vasospasm and altered arachidonic acid metabolism
3. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications
4. Platelet-activating factor (PAF): Implications for coronary heart and vascular diseases
5. Platelet response to the aggregatory effect of platelet activating factor (PAF) ex vivo in patients with acute myocardial infarction
6. Platelet aggregability to platelet activating factor at rest and after exercise in patients with coronary artery disease
7. Platelet aggregatory response to platelet aggregatory factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: Effect of c7E3 Fab (abciximab) therapy
8. Self-administration of a questionnaire on chest pain and intermittent claudication
9. Estimation of error rates in discriminant analysis
10. Neutrophil interactions with endothelium and platelets: Possible role in the development of cardiovascular injury
11. Increased neutrophil-platelet adhesion in patients with unstable angina
12. A juxtacrine mechanism for neutrophil adhesion on platelets involves platelet-activating factor and a selectin-dependent activation process
13. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin
14. Endothelial cell-associated platelet-activating factor: A novel mechanism for signaling intercellular adhesion
15. Platelet-activating factor. A fluid-phase and cell-associated mediator of inflammation
16. Inhibition of platelet glycoprotein IIb/IIIa receptors. Will they be useful when given chronically?
17. Lack of platelet-activating factor release during reversible myocardial ischaemia
18. Conformation properties of the PAF-acether receptor on platelets based on structured-activity studies
19. The role of cardiac troponin T and other new biochemical markers in evaluation and risk stratification of patients with acute biochemical markers in evaluation and risk stratification of patients with acute chest pain syndromes
20. Cardiac troponin T levels for risk stratification in acute myocardial ischaemia
21. Cardiac specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes
22. A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin-induced platelet shape change and does not enhance spontaneous platelet aggregation
23. Platelet function in patients admitted with a diagnosis of myocardial infarction
24. Pathophysiology of heparin-induced thrombocytopenia (HIT)